Core Viewpoint - The strategic cooperation agreement signed by the company with Shanghai Jinguang Enterprise Development involves an investment of up to RMB 370 million to establish a commercial production base for advanced CAR-T cell therapy products in Shanghai [1][2] Group 1: Investment and Development - The investment will support the commercialization process of multiple CAR-T cell therapy products, including the already launched product, Sai Kaize®, and the product Shurijiaolun Sai injection (proposed brand name: KailimeiTM), which is in the new drug application stage [1] - The establishment of the production base is aimed at enhancing the capacity for CAR-T cell therapy products that meet international standards, which is crucial for the commercialization of various products and strengthening global competitiveness [1] Group 2: Financial Strategy and Government Support - The transaction allows the company to avoid significant early capital expenditures, preserving valuable cash flow for core research and market expansion [1] - The strategic cooperation reflects the company's robust financial planning and deep integration into the CAR-T cell therapy industry ecosystem, aligning with national and local biopharmaceutical industry policies, receiving strong government support [2] - This collaboration is expected to further solidify the company's leading position in the global CAR-T cell therapy field and create long-term value for shareholders [2]
科济药业-B(02171.HK)拟在上海金山建设先进CAR-T生产基地 总投资不超过3.7亿元